<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Archiving and Interchange DTD v2.3 20070202//EN" "archivearticle.dtd">
<article article-type="research-article"><?properties open_access?><!-- Original-type: ra--><front><journal-meta><journal-id journal-id-type="nlm-ta">Br J Cancer</journal-id><journal-title>British Journal of Cancer</journal-title><issn pub-type="ppub">0007-0920</issn><issn pub-type="epub">1532-1827</issn><publisher><publisher-name>Nature Publishing Group</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">10944597</article-id><article-id pub-id-type="pmc">2363506</article-id><article-id pub-id-type="pii">6691316</article-id><article-id pub-id-type="doi">10.1054/bjoc.2000.1316</article-id><article-categories><subj-group subj-group-type="heading"><subject>Regular Article</subject></subj-group></article-categories><title-group><article-title>A phase II study of temozolomide vs. procarbazine in patients with glioblastoma multiforme at first relapse</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Yung</surname><given-names>W K A</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Albright</surname><given-names>R E</given-names></name><xref ref-type="aff" rid="aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Olson</surname><given-names>J</given-names></name><xref ref-type="aff" rid="aff3">3</xref></contrib><contrib contrib-type="author"><name><surname>Fredericks</surname><given-names>R</given-names></name><xref ref-type="aff" rid="aff4">4</xref></contrib><contrib contrib-type="author"><name><surname>Fink</surname><given-names>K</given-names></name><xref ref-type="aff" rid="aff5">5</xref></contrib><contrib contrib-type="author"><name><surname>Prados</surname><given-names>M D</given-names></name><xref ref-type="aff" rid="aff6">6</xref></contrib><contrib contrib-type="author"><name><surname>Brada</surname><given-names>M</given-names></name><xref ref-type="aff" rid="aff7">7</xref></contrib><contrib contrib-type="author"><name><surname>Spence</surname><given-names>A</given-names></name><xref ref-type="aff" rid="aff8">8</xref></contrib><contrib contrib-type="author"><name><surname>Hohl</surname><given-names>R J</given-names></name><xref ref-type="aff" rid="aff9">9</xref></contrib><contrib contrib-type="author"><name><surname>Shapiro</surname><given-names>W</given-names></name><xref ref-type="aff" rid="aff10">10</xref></contrib><contrib contrib-type="author"><name><surname>Glantz</surname><given-names>M</given-names></name><xref ref-type="aff" rid="aff11">11</xref></contrib><contrib contrib-type="author"><name><surname>Greenberg</surname><given-names>H</given-names></name><xref ref-type="aff" rid="aff12">12</xref></contrib><contrib contrib-type="author"><name><surname>Selker</surname><given-names>R G</given-names></name><xref ref-type="aff" rid="aff13">13</xref></contrib><contrib contrib-type="author"><name><surname>Vick</surname><given-names>N A</given-names></name><xref ref-type="aff" rid="aff14">14</xref></contrib><contrib contrib-type="author"><name><surname>Rampling</surname><given-names>R</given-names></name><xref ref-type="aff" rid="aff15">15</xref></contrib><contrib contrib-type="author"><name><surname>Friedman</surname><given-names>H</given-names></name><xref ref-type="aff" rid="aff16">16</xref></contrib><contrib contrib-type="author"><name><surname>Phillips</surname><given-names>P</given-names></name><xref ref-type="aff" rid="aff17">17</xref></contrib><contrib contrib-type="author"><name><surname>Bruner</surname><given-names>J</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Yue</surname><given-names>N</given-names></name><xref ref-type="aff" rid="aff18">18</xref></contrib><contrib contrib-type="author"><name><surname>Osoba</surname><given-names>D</given-names></name><xref ref-type="aff" rid="aff19">19</xref></contrib><contrib contrib-type="author"><name><surname>Zaknoen</surname><given-names>S</given-names></name><xref ref-type="aff" rid="aff20">20</xref></contrib><contrib contrib-type="author"><name><surname>Levin</surname><given-names>V A</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib></contrib-group><aff id="aff1"><label>1</label>Department of Neuro-Oncology, UTMD Anderson Cancer Center, Box 100, 1515 Holcombe Boulevard, Houston, Texas, 77030</aff><aff id="aff2"><label>2</label>Barret Cancer Center, 234 Goodman Street, Cincinnati, Ohio, 45267</aff><aff id="aff3"><label>3</label>Department of Neurosurgery, Emory University, 1327 Clifton Road, Atlanta, Georgia, 30322</aff><aff id="aff4"><label>4</label>University of Mississippi Medical Center, 2500 North State Street, Jackson, Mississippi, 39216</aff><aff id="aff5"><label>5</label>Department of Neurology, University of Texas, Southwestern Medical School, 5323 Harry Hines Boulevard, Dallas, Texas, 75235</aff><aff id="aff6"><label>6</label>Department of Neurosurgery, University of California San Francisco, 533 Parnassus Street, Room U107, San Francisco, CaliCityfornia, 94143</aff><aff id="aff7"><label>7</label>The Royal Marsden NHS Trust and the Institute of Cancer Research, Royal Marsden Hospital, Downs Road, Sutton, Surrey, SM2 5PT, United Kingdom</aff><aff id="aff8"><label>8</label>Department of Neurology, University of Washington, Box 356465, 1959 N.E. Pacific Street, Seattle, Washington, 98195</aff><aff id="aff9"><label>9</label>University of Iowa, Hospitals and Clinics, 200 Hawkins Drive, Iowa City, Iowa, 52242</aff><aff id="aff10"><label>10</label>Division of Neurology, Barrow Neurological Institute, 350 West Thomas Road, Phoenix, Arizona, 85013</aff><aff id="aff11"><label>11</label>Memorial Hospital of Rhode Island, 710 Robinson Road, PO Box 665, Hinsdale, Massachusetts, 01235</aff><aff id="aff12"><label>12</label>Department of Neurology, University of Michigan Medical Center, 1500 East Medical Center Drive, 1914 Taubman Center, Box 0316, Ann Arbor, Michigan, 48109</aff><aff id="aff13"><label>13</label>West Penn Hospital, Center for Neuro-Oncology, 4800 Friendship Avenue &#x02013; Suite 1614, Pittsburgh, Pennsylvania, 15224</aff><aff id="aff14"><label>14</label>Division of Neurology, Evanston Hospital, 2650 Ridge Avenue, Evanston, Illinois, 60201</aff><aff id="aff15"><label>15</label>Beatson Oncology Centre, Western Infirmary, Glasgow, G11 6NT, United Kingdom</aff><aff id="aff16"><label>16</label>Department of Pediatric Hematology-Oncology, Duke University Medical Center, Duke North &#x02013; Room 5418, Erwin Road, Durham, North Carolina, 27710</aff><aff id="aff17"><label>17</label>Department of Neuroscience, University of Pennsylvania Medical Center, Abramson 516, 3400 Civic Center Boulevard, Philadelphia, Pennsylvania, 19104</aff><aff id="aff18"><label>18</label>MRI Reading Center at St. Joseph, 8216 Carrbridge Circle, Baltimore, Maryland, 21204</aff><aff id="aff19"><label>19</label>British Columbia Cancer Agency, 1515 Larch Street, Vancouver, British Columbia, V6K 3N6, Canada</aff><aff id="aff20"><label>20</label>Schering-Plough Research Institute, 2000 Galloping Hill Road, Kenilworth, New Jersey, 07033, USA</aff><pub-date pub-type="epub"><day>16</day><month>08</month><year>2000</year></pub-date><pub-date pub-type="ppub"><month>09</month><year>2000</year></pub-date><volume>83</volume><issue>5</issue><fpage>588</fpage><lpage>593</lpage><history><date date-type="received"><day>13</day><month>08</month><year>1999</year></date><date date-type="rev-recd"><day>23</day><month>04</month><year>2000</year></date><date date-type="accepted"><day>01</day><month>05</month><year>2000</year></date></history><copyright-statement>Copyright 2000, Cancer Research Campaign</copyright-statement><copyright-year>2000</copyright-year><permissions><copyright-holder>Cancer Research Campaign</copyright-holder></permissions><abstract><p>A randomized, multicentre, open-label, phase II study compared temozolomide (TMZ), an oral second-generation alkylating agent, and procarbazine (PCB) in 225 patients with glioblastoma multiforme at first relapse. Primary objectives were to determine progression-free survival (PFS) at 6 months and safety for TMZ and PCB in adult patients who failed conventional treatment. Secondary objectives were to assess overall survival and health-related quality of life (HRQL). TMZ was given orally at 200 mg/m<sup>2</sup>/day or 150 mg/m<sup>2</sup>/day (prior chemotherapy) for 5 days, repeated every 28 days. PCB was given orally at 150 mg/m<sup>2</sup>/day or 125 mg/m<sup>2</sup>/day (prior chemotherapy) for 28 days, repeated every 56 days. HRQL was assessed using the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30 [+3]) and the Brain Cancer Module 20 (BCM20). The 6-month PFS rate for patients who received TMZ was 21&#x00025;, which met the protocol objective. The 6-month PFS rate for those who received PCB was 8&#x00025; (<italic>P</italic> = 0.008, for the comparison). Overall PFS significantly improved with TMZ, with a median PFS of 12.4 weeks in the TMZ group and 8.32 weeks in the PCB group (<italic>P</italic> = 0.0063). The 6-month overall survival rate for TMZ patients was 60&#x00025; vs. 44&#x00025; for PCB patients (<italic>P</italic> = 0.019). Freedom from disease progression was associated with maintenance of HRQL, regardless of treatment received. TMZ had an acceptable safety profile; most adverse events were mild or moderate in severity. &#x000a9; 2000 Cancer Research Campaign</p></abstract><kwd-group><kwd>malignant glioma</kwd><kwd>temozolomide</kwd><kwd>procarbazine</kwd><kwd>glioblastoma multiforme</kwd></kwd-group></article-meta></front></article>


